Predictive modelling for high-risk stage II colon cancer using auto-artificial intelligence

被引:1
|
作者
Ishizaki, Tetsuo [1 ]
Mazaki, Junichi [1 ]
Enomoto, Masanobu [1 ]
Udo, Ryutaro [1 ]
Tago, Tomoya [1 ]
Kasahara, Kenta [1 ]
Nagakawa, Yuichi [1 ]
机构
[1] Tokyo Med Univ, Dept Gastrointestinal & Pediat Surg, Shinjuku Ku, 6-7-1 Nishi, Tokyo 1600023, Japan
关键词
Predictive modelling; Stage II colon cancer; High-risk; Auto-artificial intelligence; Prediction; Adjuvant chemotherapy; ADJUVANT CHEMOTHERAPY; CONTROLLED-TRIAL; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; GUIDELINES; THERAPY; SOCIETY;
D O I
10.1007/s10151-022-02685-y
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Recently, stratification of high-risk stage II colon cancer (CC) and the need for adjuvant chemotherapy have been the focus of attention. The aim of this retrospective study was to define high-risk factors for recurrent stage II CC using Prediction One auto-artificial intelligence (AI) software and develop a new predictive model for high-risk stage II CC. Methods The study included 259 consecutive pathological stage II CC patients undergoing curative resection at our institution between January 2000 and December 2016. Prediction One software with five-fold cross-validation was used to create a predictive model and receiver operating characteristic (ROC) curve. Predictive accuracy of AI was evaluated using the area under the ROC curve (AUC). We also evaluated the importance of variables (IOV) using a method based on permutation feature importance (IOV > 0.01 defined high-risk factors) to evaluate disease-free survival (DFS). Results The median observation period was 6.1 (range = 0.3-15.8) years. Thirty-seven patients had recurrence (14.3%); the AUC of the AI model was 0.775. Preoperative carcinoembryonic antigen > 5.0 ng/mL (IOV = 0.047), venous invasion (IOV = 0.014), and obstruction (IOV = 0.012) were high-risk factors contributing to cancer recurrence. Patients with 2-3 high-risk factors had lower 5-year DFS than those with 0-1 factor (87.4% vs 62.7%, p < 0.001). Conclusions We developed a new predictive model that could predict recurrent high-risk stage II CC with high probability using auto-AI Prediction One software. Patients with >= 2 of the aforementioned factors are considered to have high risks for recurrent stage II CC and may benefit from adjuvant chemotherapy.
引用
收藏
页码:183 / 188
页数:6
相关论文
共 50 条
  • [31] Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer
    Zunder, S.
    van Pelt, G.
    Gelderblom, H.
    Tollenaar, R.
    Mancao, C.
    Mesker, W.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] The effect of gaps in chemotherapy on survival in patients with high-risk stage II and stage III colon cancer
    Sada, Yvonne
    Duan, Zhigang
    El-Serag, Hashem
    Davila, Jessica
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (34)
  • [33] Risk factors for recurrence in patients with high-risk stage II colon cancer after curative resection
    Ohge, H.
    Sadahiro, S.
    Sakamoto, K.
    Tsuchiya, T.
    Takahashi, T.
    Sato, T.
    Kondo, K.
    Ogata, Y.
    Baba, H.
    Itabashi, M.
    Ikeda, M.
    Hamada, M.
    Kusano, M.
    Hyodo, I.
    Sakamoto, J.
    Taguri, M.
    Morita, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S417 - S417
  • [34] Prognostic value of nucleotyping, DNA ploidy and stroma in high-risk stage II colon cancer
    Yang, Lujing
    Chen, Pengju
    Zhang, Li
    Wang, Lin
    Sun, Tingting
    Zhou, Lixin
    Li, Zhongwu
    Wu, Aiwen
    BRITISH JOURNAL OF CANCER, 2020, 123 (06) : 973 - 981
  • [35] Adjuvant Chemotherapy in High-risk Stage II Colon Cancer Patients: (Un) common Practice?
    Koebrugge, B.
    Van Steenbergen, L. N.
    Lips, D. J.
    Lemmens, V. E.
    Van der Linden, H. C.
    Pruijt, H. F.
    Liefers, G.
    Van de Velde, C. J.
    Bosscha, K.
    ANNALS OF SURGICAL ONCOLOGY, 2012, 19 : S103 - S103
  • [36] Adjuvant Chemotherapy for High-Risk Stage II Colon Cancer: A Population-Based Study
    Butare, Annmarie
    Sutton, Tia
    Kantzler, Elizabeth
    Kennedy, Katie N.
    Tumin, Dmitry
    Honaker, Michael D.
    JOURNAL OF GASTROINTESTINAL CANCER, 2025, 56 (01)
  • [37] Effectiveness of oral fluoropyrimidine monotherapy as adjuvant chemotherapy for high-risk stage II colon cancer
    Cho, Jung Rae
    Lee, Keun-Wook
    Oh, Heung-Kwon
    Kim, Jin Won
    Kim, Ji-Won
    Kim, Duck-Woo
    Kim, Jee Hyun
    Kang, Sung-Bum
    ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2022, 102 (05) : 271 - 280
  • [38] Elevated Carcinoembryonic Antigen Warrants Adjuvant Chemotherapy in High-risk Stage II Colon Cancer
    Wilson, Tanner B.
    Narayanan, Sowmya
    Khan, Sidrah
    Althans, Alison R.
    Paniccia, Alessandro
    Zureikat, Amer H.
    Kaltenmeier, Christof
    Lee, Kenneth K.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 2) : 380 - 380
  • [39] Clinical Implications of Mismatch Repair Status in Patients With High-risk Stage II Colon Cancer
    Baek, Dong Won
    Kang, Byung Woog
    Lee, Soo Jung
    Kim, Hye Jin
    Park, Su Yeon
    Park, Jun Seok
    Choi, Gyu Seog
    Baek, Jin Ho
    Kim, Jong Gwang
    IN VIVO, 2019, 33 (02): : 649 - 657
  • [40] High-Risk Features Are Prognostic in dMMR/MSI-H Stage II Colon Cancer
    Mohamed, Amr
    Jiang, Renjian
    Philip, Philip A.
    Diab, Maria
    Behera, Madhusmita
    Wu, Christina
    Alese, Olatunji
    Shaib, Walid L.
    Gaines, Tyra M.
    Balch, Glen G.
    El-Rayes, Bassel F.
    Akce, Mehmet
    FRONTIERS IN ONCOLOGY, 2021, 11